Saara Huoponen
University of Helsinki
11 Papers
42 Citations
Saara Huoponen is an academic researcher from University of Helsinki. The author has contributed to research in topics: Infliximab & Inflammatory bowel disease. The author has an hindex of 4, co-authored 8 publications.
Chat about Author
Papers
The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review.
TL;DR: Rituximab was found to be the most cost-effective alternative compared to other biologics among the patients with an insufficient response to TNFi, and standardization of multiattribute utility instruments and a validated standard conversion method for missing utility measures would enable better comparison between CUAs.
Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
TL;DR: Switching from originator to biosimilar inflIXimab resulted in statistically significant differences in infliximab TLs in patients with UC but not in Patients with Crohn’s disease, and the clinical significance is doubtful and in neither group changes in disease activity occurred.
Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.
Saara Huoponen,Anja Eberl,Pirjo Räsänen,Risto P. Roine,Taina Sipponen,Perttu Arkkila,Marja Blom +6 more
TL;DR: HRQoL and disease activity were after switching from originator to biosimilar IFX comparable, but the costs of biosimilarIFX were only one-third of those of the originator one, and total costs related to secondary health care were similar before and after the onset of IFX.
12
Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
Saara Huoponen,Kalle Aaltonen,Jaana Viikinkoski,Jarno Rutanen,Heikki Relas,Kirsi Taimen,Kari Puolakka,Dan Nordström,Marja Blom +8 more
TL;DR: Evaluating the cost-effectiveness of abatacept, tocilizumab, and tumor necrosis factor (TNF) inhibitors as compared with rituximab in Finnish rheumatoid arthritis patients found TNF inhibitors had the lowest costs and highest QALYs, and therefore they were the most cost-effective treatment option.